Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity
Journal of Medical Society · 2026-01 · 40 (1) · 12-17
DOI: 10.4103/jms.jms_28_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Society, online erschienen am 20.05.2026. Verfasst von Arfan Musaliyar und 4 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist that has significant effects on glycemic control and weight loss in patients with type 2 diabetes mellitus (T2DM) and obesity. Tirzepatide mimics the actions of both GIP and GLP-1, the main incretin hormones that regulate glucose homeostasis and energy balance. Materials and Methods: A systematic literature search was conducted for relevant articles published, using the terms “Tirzepatide,” “type 2 diabetes,” and “obesity.” Relevant studies were assessed for quality, and the data were extracted and synthesized using a narrative approach.
Results
Tirzepatide significantly improved glycemic control and reduced body weight in patients with T2DM and obesity compared with placebo, insulin, or other GLP-1 receptor agonists, with a reduction in hemoglobin A1c and body mass index. Additional metabolic parameters that improved included blood pressure, lipid profile, and liver function tests. Tirzepatide was generally well tolerated, with the most common adverse effects being nausea, vomiting, and diarrhea. The incidence of hypoglycemia and serious adverse events was low and comparable with control treatments.
Zitieren
APA
Musaliyar, A., Kumar, N., Terrance, S., Reni, A. R., & Padur, A. A. (2026). Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity. Journal of Medical Society, 40(1), 12-17. https://doi.org/10.4103/jms.jms_28_25
Vancouver
Musaliyar A, Kumar N, Terrance S, Reni AR, Padur AA. Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity. Journal of Medical Society. 2026;40(1):12-17. doi:10.4103/jms.jms_28_25
BibTeX
@article{Musaliyar2026,
author = {Musaliyar, Arfan and Kumar, Naveen and Terrance, Steffy and Reni, Abigail Rhea and Padur, Ashwini Aithal},
title = {Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity},
journal = {Journal of Medical Society},
year = {2026},
volume = {40},
number = {1},
pages = {12--17},
doi = {10.4103/jms.jms_28_25}
}
EUVIMED